NCT00043953已完成2 期
A Phase II Study of Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 30
- 试验地点
- 21
- 主要终点
- Proportion of subjects with plasma HIV RNA level below 50 copies/mL
研究概览
简要总结
The objectives of this study are to explore the metabolic toxicities associated with lopinavir/ritonavir (LPV/r) plus saquinavir mesylate (INV) versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the overall safety, tolerability and efficacy of LPV/r plus INV versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the pharmacokinetics of 400 mg INV taken twice a day (BID), 600 mg INV BID and 800 mg INV BID in combination with 400 mg lopinavir/100 mg ritonavir plus 150 mg lamivudine/300 mg zidovudine BID.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is naïve to antiretroviral treatment (subjects may not have more than 7 days of any antiretroviral treatment).
- •Subject is at least 18 years of age, inclusive.
- •If female, subject is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing potential and practicing one of the following methods of birth control:condoms, sponge, foams, jellies, diaphragm or intrauterine device(IUD), a vasectomized partner, total abstinence from sexual intercourse
- •If female, the results of a urine pregnancy test performed at screening (urine specimen obtained no earlier than 28 days prior to study drug administration) is negative.
- •Subject is not breast-feeding.
- •Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness.
- •Subject has no significant history of cardiac, renal, neurologic, psychiatric, oncologic, endocrinologic, metabolic or hepatic disease that would in the opinion of the investigator adversely affect his/her participating in this study.
- •Subject does not require and agrees not to take any of the following medications for the duration of the study: midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, propafenone, flecainide, certain ergot derivatives (ergotamine, dihydroergotamine, ergonovine, and methylergonovine), rifampin, lovastatin, simvastatin, and St. John's wort.
- •Subject agrees not to take any medication during the study, including over-the-counter medicine, alcohol or recreational drugs without the knowledge and permission of the principal investigator.
- •Subject has not been treated for an active AIDS-defining opportunistic infection within 30 days of screening.
- •Subject has a plasma HIV RNA level of greater than 400 copies/mL at screening.
- •Subject agrees to take all doses of the study drug from the bottles provided by the sponsor (rather than other containers, i.e., "pill box").
- •Subject has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed.
排除标准
- •Subject has a history of an allergic reaction or significant sensitivity to LPV/r, INV or Combivir.
- •Subject has a history of substance abuse or psychiatric illness that could preclude adherence with the protocol.
- •Screening laboratory analyses show any of the following abnormal laboratory results:
- •Hemoglobin ≤ 10.0 g/dL
- •Absolute neutrophil count ≤ 1000 cells/µL
- •Platelet count ≤ 50,000 per mL
- •ALT or AST ≥ 3.0 x Upper Limit of Normal (ULN)
- •Creatinine ≥ 1.5 x Upper Limit of Normal (ULN)
- •Subject has received any investigational drug within 30 days prior to study drug administration.
- •For any reason, subject is considered by the investigator to be an unsuitable candidate for the study.
结局指标
主要结局
Proportion of subjects with plasma HIV RNA level below 50 copies/mL
时间窗: 48 weeks
次要结局
未报告次要终点
研究者
研究点 (21)
Loading locations...
相似试验
已完成
1 期
Safety of Saquinavir and High Doses of Lopinavir/Ritonavir in Children With HIVHIV InfectionsNCT00084058National Institute of Allergy and Infectious Diseases (NIAID)26
终止
4 期
Pharmacokinetic Study of Two HIV Protease Inhibitors in PatientsHIV InfectionNCT00420355University of Oklahoma19
已完成
2 期
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China IIChronic Hepatitis CNCT03020004Ascletis Pharmaceuticals Co., Ltd.70
已完成
1 期
Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy VolunteersHealthyNCT02245269Boehringer Ingelheim23
终止
4 期
Pilot Assessment of Lopinavir/Ritonavir and MaravirocAcquired Immunodeficiency SyndromeHIV InfectionsNCT00981318Rodwick, Barry M., M.D.3